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BACKGROUND: Despite accurate diagnostic tests and
effective therapies, the management of osteoporosis has
been observed to be suboptimal in many settings. We
tested the effectiveness of an intervention to improve
care in patients at-risk of osteoporosis.
DESIGN: Randomized controlled trial.
PARTICIPANTS: Primary care physicians and their
patients at-risk of osteoporosis, including women
65 years and over, men and women 45 and over with
a prior fracture, and men and women 45 and over who
recently used ≥90 days of oral glucocorticoids.
INTERVENTION: A multifaceted program of education
and reminders delivered to primary care physicians as
well as mailings and automated telephone calls to
patients. Outcome: Either undergoing a bone mineral
density (BMD) testing or filling a prescription for a bone-
active medication during the 10 months of follow-up.
RESULTS: After the intervention, 144 (14%) patients in
the intervention group and 97 (10%) patients in the
control group received either a BMD test or filled a
prescription for an osteoporosis medication. This repre-
sents a 4% absolute increase and a 45% relative
increase (95% confidence interval 9–93%, p=0.01) in
osteoporosis management between the intervention and
control groups. No differences between groups were
observed in the incidence of fracture.
CONCLUSION: An intervention targeting primary care
physicians and their at-risk patients increased the
frequency of BMD testing and/or filling prescriptions
for osteoporosis medications. However, the absolute
percentage of at-risk patients receiving osteoporosis
management remained low.
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D
espite accurate diagnostic techniques and effective
treatments, many at-risk populations do not receive
management for osteoporosis. Studies of postfracture popula-
tions document screening and treatment rates below 20%
in most settings.
1–4 Management of glucocorticoid-induced
osteoporosis has also been observed to be suboptimal.
5–7 The
relatively straightforward methods for diagnosis and treat-
ment and the huge unmet need suggest that osteoporosis
should initially be managed by primary care physicians in
most instances.
8 However, previous assessments found that
primary care physicians often regard osteoporosis as a low
priority, and many do not see the value in screening and
treatment.
9
Several trials aimed at improving osteoporosis manage-
ment have been published.
10–17 These have focused on
educating patients, scheduling bone mineral density (BMD)
testing, and posttest counseling. Many of these interventions
appear effective, but few have been evaluated in randomized
controlled trials, most have been tested in a single site, and
the ability to widely implement such programs may be
limited. We designed and tested an educational program
targeting primary care physicians and their at-risk patients
to improve osteoporosis management. Principles of academic
detailing, including one-on-one adult learning with action-
oriented messages, guided design of the intervention.
18 We
tested our multifaceted program to improve osteoporosis
management among primary care physicians in a randomized
controlled trial.
METHODS
Study Design
We conducted a randomized controlled trial among primary
care physicians and their at-risk patients. All patients in the
study group were beneficiaries of a large health care insurer,
Horizon Blue Cross Blue Shield of New Jersey (HBCBSNJ). In
addition, they were all considered at-risk of osteoporosis (see
Study Population for details) and had not undergone bone
mineral density (BMD) testing nor received a medication for
osteoporosis during a 26-month baseline period. To improve
the efficiency of our physician-targeted intervention, only
primary care physicians with at least 4 at-risk beneficiaries
were selected for randomization. The intervention occurred
over a 3-month period, September 1, 2004–November 30,
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3622004, and endpoints were assessed over 10 months, beginning
with the start of the intervention through June 24, 2005.
All aspects of the trial were approved by the Partners
Healthcare Institutional Review Board.
Intervention
The maininterventionconsisted ofone-on-one educational visits
with primary care physicians. The visits were conducted by
specially trained pharmacists who work with HBCBSNJ as
physician educators. These pharmacists also underwent a 1-
day training program focused on osteoporosis and conducted by
2 of the study authors. This program included lectures on the
epidemiology, diagnosis, and treatment of osteoporosis. Also, it
reviewed principles of academicdetailing
18 and the specific goals
of this intervention. Mock scripts were used for practicing
physician encounters, and several follow-up teleconferences
were conducted to review materials, practice educational
encounters, and provide logistical support to the educators.
We developed a continuing medical education (CME) program
(accredited by Harvard Medical School’s CME department) that
was distributed in the setting of the physician visit. The
materials consisted of brief summaries of osteoporosis epidemi-
ology, diagnosis, and treatment. Also, we provided doctors with
an algorithm for diagnosis and treatment of osteoporosis and a
guide to osteoporosis pharmacotherapy. A version of this
material was reproduced on 1 double-sided laminated card
small enough to fit into a coat pocket. The educators also offered
the doctors and their staff “tear sheets” for patients that
resembledprescriptionpadswithcheckboxesforfallprevention,
calcium and vitamin D use, bone mineral density testing, and
treatment. We supplied patient materials on fall prevention to
the primary care physician’s office staff. (All materials available
upon request.) In addition, the study paid for doctors to apply for
CME credit if they completed a postvisit test.
Each primary care physician in the intervention groups
received a list of her HBCBSNJ patients at-risk for osteoporo-
sis. The educators used this list during the one-on-one visit
with doctors to give examples of patients that should be
considered for BMD testing and/or treatment.
Patients in the intervention group received an introductory
letter from HBCBSNJ and then an automated telephone call
from HBCBSNJ inviting them to undergo BMD testing. This
call employed interactive voice response technology that has
been used for other screening tests.
19 We have described this
aspect of the intervention in detail in another related paper.
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Such automated calling provides tailored education through a
branching logic algorithm. For example, persons who had
never had a BMD test but expressed an interest were offered
specific encouragement, “it’s great that you plan on having a
bone density test; the best way to tell if a person is at risk for
osteoporosis is to have a bone density test. The test only takes
about 5 minutes, you don’t have to take off your clothes, and
it’s painless.” At the conclusion of the educational call,
patients were able to transfer directly to a centralized radiology
service to schedule a BMD test.
Study Population
The assembly of the study population is described in Fig. 1.
Our goal was to identify at-risk patients who had not recently
received osteoporosis management, either a BMD test or a
medication for osteoporosis. The initial study population
consisted of beneficiaries of HBCBSNJ who had at least 2
continuous years of enrollment before the intervention and a
prescription drug benefit. To ensure that subject’s prescription
drug claims were through HBCBSNJ, we required that they
filed at least 1 prescription claim with HBCBSNJ in each of the
2 baseline years. Patients who were Medicare beneficiaries
enrolled in HBCBSNJ would have all of their health care claims
paid by HBCBSNJ.
From this group of patients, we identified populations at-risk
for osteoporosis using demographic information and health care
utilization data, such as diagnoses, medication use, surgical
procedures, and hospitalizations. The at-risk groups included:
women 65 years of age and over; women and men 45 and older
with a prior fracture of the hip, spine, forearm, or humerus; and
women and men 45 and older who had used oral glucocorticoids
for at least 90 days. These determinations were based on data
from the 26-month baseline period.
To improve the efficiency of our intervention, 2 further
exclusions were applied. First, patients who had undergone a
BMD test or filled at least 1 prescription for an osteoporosis
medication during the baseline 26 months were excluded.
Because the study dataset does not permit clear determination
of this group’s need for further management, the analyses
focused on the population who had neither undergone BMD
testing nor filled a prescription for an osteoporosis medication
during the baseline period. Second, we excluded patients whose
primary care physicians (as listed by HBCBSNJ) had less than 4
eligible HBCBSNJ beneficiaries at-risk for osteoporosis.
Study Outcome and Covariates
Bone mineral density (BMD) testing and use of an osteoporosis
medication formed the main study outcome. Osteoporosis
medications included hormone therapy, calcitonin, raloxifene,
bisphosphonates, and teriparatide. Each component of the
main outcome was examined individually.
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using the health care utilization information. These data includ-
ed demographics, physician and hospital visits, diagnoses and
procedures such as prior fractures, comorbid conditions,
21
laboratory and radiology tests (i.e., BMD tests), and prescription
medication use. In addition, we examined the characteristics of
primary care physicians in both groups. All patients in
HBCBSNJ must designate a primary care provider. Eligible
primary care providers include subspecialists of Internal Medi-
cine, such as endocrinologists and rheumatologists.
Statistical Analyses
We compared the intervention and control groups in their
baseline characteristics. The effect of the intervention was
determined using a regression model that accounted for the
clustered structure of the data. Because patients are clustered
within a given primary care physician’s practice, we used a
Generalized Estimating Equations approach with a working
variance–covariance matrix that assumed an independent struc-
ture. Subgroup analyses focused on the different at-risk groups:
women65 and over, men and womenwitha fracture,ormen and
women who used oral glucocorticoids. These groups are not
mutually exclusive. Both unadjusted and adjusted analyses
(controlling for baseline covariates) were performed in PROC
GENMOD in SAS Version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
The eligible study population included 4,266 patients and their
458 primary care physicians. As noted in Fig. 1, 2,293 (54%)
underwent a BMD test or received an osteoporosis medication
duringthebaselineperiod,andtheprimaryanalysesfocusonthe
remaining 1,973 patients and their 434 primary care physicians.
The intervention and control groups were well balanced with
r e s p e c tt om o s tc h a r a c t e r i s t i c s( T a b l e1). As expected, the mean
age of patients was approximately 70 and more than 90% were
female. During the baseline period, 1 in 10 patients had a prior
fracture and about one-quarter had used oral glucocorticoids.
Theaverage primarycare physicianwas 50 years old,a man, and
trained in Internal Medicine. About one-third trained in family
practice. Only 6 physicians in total (3 in intervention and 3 in
control) subspecialized in endocrinology or rheumatology.
In Table 2, we present the results of the intervention,
showing small absolute but large relative effects. Patients in
the intervention group were significantly more likely to under-
go BMD testing (all tests were for dual energy x-ray absorpti-
ometry), receive a medication for osteoporosis, or have had at
least 1 of these outcomes than patients in the control group.
The relative increases ranged from 43% to 60%, but the
absolute increases were small. To understand whether the
slight baseline imbalances between intervention and control
groups might have affected our results, we ran adjusted
models that controlled for baseline covariates (see Table 2);
these results were very similar to the unadjusted findings.
Table 3 shows the results from subgroup analyses. The
effects of the intervention among women 65 years and older
and people with a prior fracture were consistent with, if not
slightly stronger than, the results among the total population.
The intervention may not have been effective among the
subgroup of patients who had used glucocorticoids; however,
small sample size in several of the subgroups precludes
definitive statements regarding the intervention’s effect.
In an attempt to understand the effects of the different parts
of the multifaceted intervention, we examined the success of the
one-on-one educational sessions with physicians and the
automated telephone calls to schedule BMD tests with patients.
Of the physicians in the intervention group, we were able to
conduct educational visits with 94% of them. These visits
averaged 15 minutes (standard deviation=9). The automated
telephone calls to patients in the intervention arm resulted in
708 calls successfully reaching the correct person. Of these
patients, 54 transferred to schedule a BMD test, but only 3
made an appointment for a BMD test while on the telephone.
DISCUSSION
We conducted a randomized controlled trial to improve osteo-
porosis care in at-risk patients by their primary care physi-
cians. The intervention combined one-on-one education for
physicians with patient-specific recommendations and a pa-
tient-targeted automated telephone program for scheduling
BMD tests. Patients seen by physicians in the intervention
group were 45% more likely than those in the control group to
Table 1. Characteristics of Patients and Physicians Based on Data
from the 2 Years Prior to the Intervention
Intervention Control P value
Patient characteristics N (%) or mean ± standard deviation
N 997 976
Age, years 68 ± 9 69 ± 8
Female gender 895 (90) 922 (94) < .001
Physician visits 13 (7, 22) 13 (6, 22) .7
Number of medications,
median (IQR)
12 (7, 18) 11 (7, 18) .5
Fractures 134 (13) 95 (10) .01
Use of oral glucocorticoids 237 (24) 199 (20) .07
Comorbid conditions,
median (IQR)
1 (0, 2) 1 (0, 2) .1
Physician characteristics
N 222 212
Number of at-risk
patients, median (IQR)
4 (2, 5) 3 (2, 5) .08
Age 50 ± 9 50 ± 10 .7
Female gender 40 (18) 33 (16) .5
Training* .3
Family medicine 87 (39) 69 (33)
Internal medicine 99 (44) 101 (48)
Internal medicine subspecialty 37 (17) 42 (20)
Patient characteristics were based on data from the 26-month baseline
period. P values are from chi-square tests for categorical data. For
continuous variables, p values were taken from Student’s t test for
normally distributed data and from Wilcoxon 2-sample test for non-
normal data. Comorbid conditions were categorized based on reference #
21.
*The training categories are mutually exclusive. Family medicine
subspecialists (n=8) are grouped into family medicine. Endocrinologists
(n=4) and rheumatologists (n=2) are grouped into Internal Medicine
subspecialist; they were equally distributed between intervention and
control groups.
BMD=bone mineral density; IQR=interquartile range
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during follow-up; however, this translated into only a 4%
absolute increase. Similar increases were also observed in the
subgroup of patients with prior fractures, exactly the group
that the National Committee on Quality Assurance has chosen
to focus on.
3
Several aspects of this intervention should be carefully
examined. First, was the correct population studied? We
targeted at-risk patients seen by primary care physicians who
had not undergone testing and/or received a medication for
osteoporosis in the prior 26 months. It is possible that these
patients had been offered testing and/or treatment and
declined such management. We could have focused on
patients who recently sustained a fracture, but our goal was
to include a broader cohort of at-risk patients. However, by
targeting patients who had not recently sustained a fracture
and who had not received testing or treatment during the
baseline period, we focused on a group that may have been
particularly difficult to reach with a quality improvement
program. They represent a large and relevant target for such
an intervention, but our relatively low absolute improvement
may be partly attributable to these factors. Second, was the
intervention appropriate?
Academic detailing has been found effective for improving
physician behavior associated with many clinical situations.
22–25
It provides one-on-one education that is both patient-specific
and can be generalized across a physician’s practice. Some
question the transferability of academic detailing. It is labor
intensive and requires an infrastructure to be successful.
However, based on a vast literature, it is one of the reliable
Table 3. Management of Osteoporosis During Follow-up Among Selected Subgroups
Subgroup endpoint Intervention Control Unadjusted results Adjusted results
Relative risk of endpoint among
intervention versus control (95% CI)
p
value
Relative risk of endpoint among
intervention versus control (95% CI)
p
value
N (%)
Women 65 and over
N 819 861
Underwent BMD
test
115 (14) 81 (9) 1.49 (1.09–2.04) .02 1.48 (1.07–2.04) .02
Medication for
osteoporosis
54 (7) 35 (4) 1.67 (1.05–2.65) .03 1.65 (1.04–2.62) .03
Either one 131 (16) 92 (11) 1.59 (1.14–2.22) .006 1.50 (1.11–2.03) .008
Men or women with fractures
N 134 95
Underwent BMD
test
11 (8) 4 (4) 1.95 (0.64–6.00) .2 2.86 (1.15–7.07) .02
Medication for
osteoporosis
6 (4) 1 (1) 4.41 (0.52–37) .2 10.67 (0.81–141) .07
Either one 13 (10) 5 (5) 1.93 (0.67–5.66) .2 2.73 (1.19–6.28) .02
Men or women using oral glucocorticoids
N 237 199
Underwent BMD
test
23 (10) 19 (10) 1.02 (0.57–1.82) .9 1.05 (0.57–1.93) .9
Medication for
osteoporosis
14 (6) 15 (8) 0.77 (0.38–1.58) .5 0.92 (0.45–1.87) .8
Either one 32 (14) 24 (12) 1.14 (0.64–2.01) .7 1.29 (0.78–2.13) .3
These subgroup analyses consisted of the 1,680 women 65 and over, 229 men or women with fractures, and the 436 men or women who used oral
glucocorticoids who did not undergo a BMD test or receive a medication during the 26-month baseline period. These subgroups are not mutually exclusive.
These analyses account for the clustering of patients within physicians’ practices using Generalized Estimating Equations.
RR=relative risk; CI=confidence interval
Table 2. Management of Osteoporosis During Follow-up
Intervention
(n=997)
Control
(n=976)
Unadjusted results Adjusted results
Relative risk of endpoint among
intervention versus control (95% CI)
p
value
Relative risk of endpoint among
intervention versus control (95% CI)
p
value
N (%)
Underwent BMD
test
126 (13) 86 (9) 1.43 (1.06–1.94) .02 1.48 (1.08–2.04) .01
Medication for
osteoporosis
59 (6) 36 (4) 1.60 (1.04–2.49) .03 1.73 (1.09–2.75) .02
Either of the above 144 (14) 97 (10) 1.45 (1.09–1.93) .01 1.52 (1.13–2.05) .006
The relative risk refers to the increase in likelihood that a subject in the intervention group would receive osteoporosis management compared with the
control subjects. These analyses account for the clustering of patients within physicians’ practices using Generalized Estimating Equations.
BMD=bone mineral density; RR=relative risk; CI=confidence interval.
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23–25 Australia has a nationwide
academic detailing program that has been successfully running
for approximately 10 years, and 5 provinces in Canada also
have similar program. Recently, 2 US states (Kentucky and
Pennsylvania) have embarked on broad-based academic detail-
ing programs as well. Thus, whereas the intervention we tested
is not easily reproduced, many health systems around the
world have embraced academic detailing because of its proven
benefits and thus our intervention may become increasingly
relevant.
The interactive voice recognition (IVR) calls to the patients
did not appear effective. Whereas this technology appears
useful for reminding patients about routine screening, such
as mammograms and pap smears,
19 it may not be optimal
when patients require more than a reminder. Because many
patients are not familiar with BMD testing, we did include an
educational component to the IVR calls, but still they did not
prompt many patients to schedule these tests.
The absolute increase of 4% in osteoporosis management
may not be clinically important. These differences represent
large relative increases after a brief intervention among
patients who may be somewhat recalcitrant. But, only 14% of
the at-risk patients that were included in the intervention
group underwent BMD testing or received a medication. Thus,
even our statistically significant increase may not be large
enough to translate into clinically meaningful improvement.
The cost of this intervention was substantial. The materials,
mailing, training, and visit costs were approximately $40,000
for this start-up program. Whereas these costs are high partly
because of the expense of initiating a program, it is not clear
that a 4% increase in screening and/or treatment of osteopo-
rosis is worth this investment. If the program was run for long
enough and actual fracture rates were reduced, the program
may reduce overall costs to a health system. Because we did
not perform a formal cost-effectiveness analysis, these com-
ments are speculative.
Our findings are limited by the fact that we focused on 2
process measures—BMD testing and medication use—and not
actual clinical endpoints, such as fracture. We did not see any
differences in fracture rates between the 2 groups, but the
study was not powered for this outcome. The effectiveness of
osteoporosis treatments suggests that the fracture rates would
decrease in the intervention group if the medication use
persisted. However, osteoporosis medication persistence is
suboptimal.
26 Receipt of a BMD test and/or use of a medica-
tion for osteoporosis define the outcome adopted by the
National Committee on Quality Assurance for their HEDIS
criteria.
3 Reliance on health care utilization data and not
clinical records probably misclassified some patients as at-risk
for osteoporosis who may not have been. We may have missed
some heal ultrasound tests that patients may have obtained
without insurance coverage. Also, we did not have information
on over-the-counter use of calcium and vitamin D supplements,
hip protectors, or advice offered by a health care provider.
However, by using health care utilization data and not medical
records, we required fewer resources for identifying at-risk
patients and their outcomes. It is also possible that a longer
follow-up period would have yielded more complete information.
Other interventions targeting improvement for the manage-
ment of osteoporosis have employed different interventions.
Gardner and colleagues also employed an education and
reminder program that was found successful.
16 This ran-
domized trial enrolled 80 patients admitted to 1 medical center
after a hip fracture. All patients received a brief educational
session; this session included a printed copy of 5 questions to
bring to their primary care physician for intervention patients.
Six weeks after Surgery intervention, patients received a follow-
up reminder telephone call. During 6 months of follow-up, 42%
of intervention patients had their osteoporosis managed com-
pared with 19% in the control arm. Several other osteoporosis
interventions have also found benefits larger than what we
observed, from 1% to 40%.
10–13,15,17
It may be the case that the results of an academic detailing
approach such as ours could be improved by also incorporating
direct to patient education. We tried to use the IVR approach for
patient education, but face-to-face delivery of information may
be more effective. Furthermore, other interventions for quality
improvement should consider financial incentives for patients
who undergo screening studies. Automated reminders for
doctors has also been effective in some settings.
17
In most populations studied, the gap between accepted
recommendations for osteoporosis care and current practice is
wide. Moreover, the population at-risk for osteoporosis is
large.
27 This translates into a pressing need for large-scale
quality improvement programs. The relative increases in
osteoporosis management that our intervention produced were
significant, but the absolute increases were small. It will
require longer follow-up to determine whether these improve-
ments are sustained and produce reductions in fractures. We
believe that one of the reasons for this intervention’s relative
success was a high rate of one-on-one physician visits. It will
be important to attempt to replicate these findings among
different primary care physicians serving various patient
populations. Randomized controlled testing of more potent
interventions, perhaps that include point-of-care reminders
and incentive programs for physicians, should lead to im-
proved processes of care that result in better patient outcomes.
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